Freed vs Eli Lilly

Side-by-side comparison of AI visibility scores, market position, and capabilities

Eli Lilly leads in AI visibility (81 vs 57)
Freed logo

Freed

ChallengerHealthcare Tech

AI Medical Documentation

AI medical scribe used by 20,000+ clinicians at $99/mo. $20M+ ARR. 32M+ patient visits transcribed. $30M Series A led by Sequoia Capital. Founded 2022, SF. Private.

AI VisibilityBeta
Overall Score
C57
Category Rank
#154 of 596
AI Consensus
74%
Trend
stable
Per Platform
ChatGPT
62
Perplexity
54
Gemini
54

About

Freed is an AI medical scribe founded in 2022 by CEO Erez Druk, headquartered in San Francisco. The platform listens to patient-clinician encounters and automatically generates structured clinical notes including SOAP notes, referral letters, patient instructions, and ICD-10/CPT billing codes. Priced at $99/month per clinician vs $25-50/hour for human scribes.

Full profile
Eli Lilly logo

Eli Lilly

LeaderHealthcare

General

Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A81
Category Rank
#17 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
80
Perplexity
75
Gemini
77

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.

Full profile

AI Visibility Head-to-Head

57
Overall Score
81
#154
Category Rank
#17
74
AI Consensus
71
stable
Trend
stable
62
ChatGPT
80
54
Perplexity
75
54
Gemini
77
62
Claude
86
55
Grok
85

Key Details

Category
AI Medical Documentation
General
Tier
Challenger
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Freed
AI Medical Documentation

Integrations

Both integrate with
Only Freed
Eli Lilly is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.